Anti-CD22 chimeric antigen receptors
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsRimas J. Orentas, Crystal L. Mackall, Ira H. Pastan
Life of this patent
Estimating the term…
Abstract
The disclosure provides a chimeric antigen receptor (CAR) comprising a) an antigen binding domain of HA22, a transmembrane domain, and an intracellular T cell signaling domain; or b) an antigen binding domain of BL22, a transmembrane domain, and an intracellular T cell signaling domain comprising CD28 and/or CD137. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
Claims20
A chimeric antigen receptor (CAR) comprising the amino acid sequence of any one of SEQ ID NO:
- 15-18 and 32.
Dependencies are inferred from the claim text.